Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Executive Summary
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.
You may also be interested in...
UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
Mixed Support For ABPI's UK Price Scheme Proposals
The UK pharma industry body has set out bold proposals for a new drug pricing agreement from 2024, but not everyone is convinced. Generics companies are pressing for more of a say in the negotiations, while patient groups want to know more about how the deal would help improve access to medicines.
Former NICE Exec Proposes New UK Fund For ‘High-Impact’ Drugs
Some of the rebates paid by drug companies to the government on their sales of medicines could be placed in a central fund to pay for drugs of “demonstrable benefit,” according to Andrew Dillon.